Common infectious agents prevalence in antiphospholipid syndrome

Lupus

Volumn 18, Issue 13, 2009, Pages 1149-1153

  Zinger, H ^a,b   Sherer, Y ^a,b   Goddard, G ^a,b   Berkun, Y ^a,b   Barzilai, O ^a,b   Agmon Levin, N ^a,b   Ram, M ^a,b   Blank, M ^a,b   Tincani, A ^a,b   Rozman, B ^a,b   Cervera, R ^a,b   Shoenfeld, Y ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antibody; Antiphospholipid syndrome; Cytomegalovirus; Epstein Barr virus; Infection; Rubella; Syphilis; Toxoplasma

Indexed keywords

EARLY ANTIGEN; IMMUNOGLOBULIN M ANTIBODY; PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; HUMAN; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; RUBELLA; SYPHILIS; TOXOPLASMA; TOXOPLASMA GONDII;

ANTIBODIES, PROTOZOAN; ANTIBODIES, VIRAL; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; IMMUNOGLOBULIN M; INFECTION; PREGNANCY; RUBELLA; THROMBOSIS; TOXOPLASMA;

EID: 71049185500     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309345738     Document Type: Article

References (58)

1. Pierangeli SS, Chen PP, Raschi E., et al. Antiphospholipid antibodies and the antiphospholipid syndrome: Pathogenic mechanisms. Semin Thromb Hemost 2008; 34: 236-250.
2. Miyakis S., Lockshin MD, Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
3. Edwards CJ, Hughes GR Hughes syndrome (the antiphospholipid syndrome): 25 years old. Mod Rheumatol 2008; 18: 119-124.
4. Atanassova PA Antiphospholipid syndrome and vascular ischemic (occlusive) diseases: An overview. Yonsei Med J 2007; 48: 901-926.
5. Asherson RA, Cervera R., Merrill JT, Erkan D. Antiphospholipid antibodies and the antiphospholipid syndrome: Clinical significance and treatment. Semin Thromb Hemost 2008; 34: 256-266.
6. Harris EN, Pierangeli SS Primary, secondary, and catastrophic antiphospholipid syndrome: What's in a name? Semin Thromb Hemost 2008; 34: 219-226.
7. Ortega-Hernandez OD, Agmon-Levin N., Blank M., Asherson RA, Shoenfeld Y. The physiopathology of the catastrophic antiphospholipid (Asherson's) syndrome: Compelling evidence. J Autoimmun 2009; 32: 1-6.
8. Sène D., Piette JC, Cacoub P. Antiphospholipid antibodies, antiphospholipid syndrome and viral infections. Rev Med Interne 2009; 30: 135-141.
9. Sherer Y., Blank M., Shoenfeld Y. Antiphospholipid syndrome (APS): Where does it come from? Best Pract Res Clin Rheumatol 2007; 21: 1071-1078.
10. Levy Y., Almog O., Gorshtein A., Shoenfeld Y. The environment and antiphospholipid syndrome. Lupus 2006; 15: 784-790.
11. Münz C., Lünemann JD, Getts MT, Miller SD Antiviral immune responses: Triggers of or triggered by autoimmunity? Nat Rev Immunol 2009; 9: 246-258.
12. Ercolini AM, Miller SD The role of infections in autoimmune disease. Clin Exp Immunol 2009; 155: 1-15.
13. Cooke A. Infection and autoimmunity. Blood Cells Mol Dis 2009; 42: 105-107.
14. Barzilai O., Ram M., Shoenfeld Y. Viral infection can induce the production of autoantibodies. Curr Opin Rheumatol 2007; 19: 636-643.
15. Wucherpfennig KW Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest 2001; 108: 1097-1104.
16. Kamradt T., Göggel R., Erb KJ Induction, exacerbation and inhibition of allergic and autoimmune diseases by infection. Trends Immunol 2005; 26: 260-267.
17. Blank M., Asherson RA, Cervera R., Shoenfeld Y. Antiphospholipid syndrome infectious origin. J Clin Immunol 2004; 24: 12-23.
18. Uthman IW, Gharavi AE Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum 2002; 31: 256-263.
19. Cervera R., Piette JC, Font J., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019-1027.
20. Espinosa G., Bucciarelli S., Asherson RA, Cervera R. Morbidity and mortality in the catastrophic antiphospholipid syndrome: pathophysiology, causes of death, and prognostic factors. Semin Thromb Hemost 2008; 34: 290-294.
21. Cervera R., Bucciarelli S., Espinosa G., et al. Catastrophic antiphospholipid syndrome: Lessons from the "CAPS Registry"-a tribute to the late Josep Font. Ann NY Acad Sci 2007; 1108: 448-456.
22. Blank M., Krause I., Fridkin M., et al. Bacterial induction of autoantibodies to beta-2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2002; 109:797-804.
23. Gharavi AE, Pierangeli SS, Espinola RG, et al. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum 2002; 46: 545-552.
24. Gharavi EE, Chaimovich H., Cucurull E., et al. Induction of antiphospholipid antibodies by immunization with synthetic viral and bacterial peptides. Lupus 1999; 8: 449-455.
25. Bakimer R., Fishman P., Blank M., Sredni B., Djaldetti M., Shoenfeld Y. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anti-cardiolipin antibody (H-3). J Clin Invest 1992; 89: 1558-1663.
26. Shoenfeld Y. Induction of experimental primary and secondary antiphospholipid syndromes in naive mice. Am J Reprod Immunol 1992; 28: 219-221.
27. Lunardi C., Tinazzi E., Bason C., Dolcino M., Corrocher R., Puccetti A. Human parvovirus B19 infection and autoimmunity. Autoimmun Rev 2008; 8: 116-120.
28. Thomas MA, Frampton G., Isenberg DA, et al. A common anti-DNA antibody idiotype and anti-phospholipid antibodies in sera from patients with schistosomiasis and filariasis with and without nephritis. J Autoimmun 1989; 2: 803-811.
29. Hojnik M., Gilburd B., Ziporen L., et al. Anticardiolipin antibodies in infections are heterogeneous in their dependency on beta 2-glycoprotein I: Analysis of anticardiolipin antibodies in leprosy. Lupus 1994; 3: 515-521.
30. Lennette ET Epstein-Barr virus. In: Murray PR, Baron EJ, Jorgensen JH, et al. (eds), Manual of Clinical Microbiology. Vol. 2, 8 th edn. Washington, DC: ASM Press; 2003. p. 1331-1340.
31. Evans AS E.B. virus antibody in systemic lupus erythematosus. Lancet 1971; 1: 1023-1024.
32. Poole BD, Scofield RH, Harley JB, et al. Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity 2006; 39: 63-70.
33. Harley JB, Harley IT, Guthridge JM, et al. The curiously suspicious: A role for Epstein-Barr virus in lupus. Lupus 2006;15: 768-777.
34. Costenbader KH, Karlson EW Epstein-Barr virus and rheumatoid arthritis: is there a link? Arthritis Res Ther 2006; 8: 1186-1193.
35. Levin LI, Munger KL, Rubertone MV, et al. Multiple sclerosis and Epstein-Barr virus. JAMA 2003; 289: 1533-1536.
36. Haahr S., Hollsberg P. Multiple sclerosis is linked to Epstein-Barr virus infection. Rev Med Virol 2006; 16: 297-310.
37. Padalko EY, Bossuyt X. Anti-dsDNA antibodies associated with acute EBV infection in Sjogren's syndrome. Ann Rheum Dis 2001; 60: 992.
38. Trimeche M., Ziadi S., Amara K., et al. Prevalence of Epstein-Barr virus in Sjögren's syndrome in Tunisia. Rev Med Interne 2006; 27: 519-523.
39. Vrbikova J., Janatkova I., Zamrazil V., Tomiska F., Fucikova T. Epstein-Barr virus serology in patients with autoimmune thyroiditis. Exp Clin Endocrinol Diabetes 1996; 104: 89-92.
40. Barzilai O., Sherer Y., Ram M., Izhaky D., Anaya JM, Shoenfeld Y. Epstein-Barr virus and cytomegalovirus in autoimmune diseases: Are they truly notorious? A preliminary report. Ann NY Acad Sci 2007; 1108: 567-577.
41. Sekigawa I., Nawata M., Seta N., Yamada M., Iida N., Hashimoto H. Cytomegalovirus infection in patients with systemic lupus erythematosus. Clin Exp Rheumatol 2002; 20: 559-564.
42. Filippi C. Von Herath MILIPPI. How viral infections affect the autoimmune process leading to type 1 diabetes. Cell Immunol 2005; 233: 125-132.
43. Roberts BW, Cech I. Association of type 2 diabetes mellitus and seroprevalence for cytomegalovirus. South Med J 2005; 98: 886-692.
44. Criscuoli V., Rizzuto MR, Cottone M. Cytomegalovirus and inflammatory bowel disease: Is there a link? World J Gastroenterol 2006; 12: 4813-4818.
45. Randone SB, Guiducci S, Cerinic MM. Systemic sclerosis and infections. Autoimmun Rev 2008; 8: 36-40.
46. Randone SB, Guiducci S., Cerinic MM Systemic sclerosis and infections. Autoimmun Rev 2008; 8: 36-40.
47. Uthman I., Tabbarah Z., Ghravani AE Hughes syndrome associated with cytomegalovirus infection. Lupus 1999; 8: 775-777.
48. Romero-Piffiguer MD, Ferro ME, Riera CM Potentiation of autoimmune response in rats infected with Toxoplasma gondii. Inhibition of suppressor system and impairment of thymic cellular populations. Autoimmunity 1990; 6: 161-172.
49. Romero-Piffiguer M., Ferro ME, Riera CM Potentiation of autoimmune response in rats infected with Toxoplasma gondii. Effect of the infection route. Jpn J Med Sci Biol 1987; 40: 175-185.
50. Tozzoli R., Barzilai O., Ram M., et al. Infections and autoimmune thyroid diseases: Parallel detection of antibodies against pathogens with proteomic technology. Autoimmun Rev 2008; 8: 112-115.
51. Desailloud R., Hober D. Viruses and thyroiditis: An update. Virol J 2009; 12: 5.
52. Agrawal N., Naithani R., Mahapatra M. Rubella infection with autoimmune hemolytic anemia. Indian J Pediatr 2007; 74: 495-496.
53. Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine 2001; 23: 3876-3886.
54. Rubinstein E. Vaccination and autoimmune diseases: The argument against. Israel Med Assoc J 2004; 6: 433-435.
55. Borchers AT, Keen CL, Shoenfeld Y., Silva J. Jr, Gershwin ME Vaccines, viruses, and voodoo. J Investig Allergol Clin Immunol 2002; 12: 155-168.
56. Shoenfeld Y., Aron-Maor A. Vaccination and autoimmunity - 'vaccinosis': a dangerous liaison? J Autoimmun 2000; 14: 1-10.
57. Cohen AD, Shoenfeld Y. Vaccine-induced autoimmunity. J Autoimmun 1996; 9: 699-703.
58. Lafond RE, Lukehart SA Biological basis for syphilis. Clin Microbiol Rev 2006; 19: 29-49.